Monoclonal gammopathy of undetermined significance secondary prevention

Jump to navigation Jump to search

Monoclonal gammopathy of undetermined significance Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Monoclonal gammopathy of undetermined significance from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Monoclonal gammopathy of undetermined significance secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Monoclonal gammopathy of undetermined significance secondary prevention

on Monoclonal gammopathy of undetermined significance secondary prevention

Monoclonal gammopathy of undetermined significance secondary prevention in the news

Blogs on Monoclonal gammopathy of undetermined significance secondary prevention

Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance

Risk calculators and risk factors for Monoclonal gammopathy of undetermined significance secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[3]

Overview

Secondary prevention includes measures to delay the progression of MGUS to active multiple myeloma.

Secondary Prevention

Secondary prevention includes measures to delay the progression of MGUS to active multiple myeloma. Laboratory tests and physical examination are routinely performed. Laboratory testing includes[1]:

References

  1. Tate JR, Graziani MS, Mollee P, Merlini G (2016). "Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies". Clin Chem Lab Med. 54 (6): 899–905. doi:10.1515/cclm-2016-0268. PMID 27107838.

Template:WH Template:WS